OCI-5/GPC3, a Glypican Encoded by a Gene That Is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line–specific Manner

OCI-5/GPC3 is a member of the glypican family. Glypicans are heparan sulfate proteoglycans that are bound to the cell surface through a glycosyl-phosphatidylinositol anchor. It has recently been shown that the OCI-5/GPC3 gene is mutated in patients with the Simpson-Golabi-Behmel Syndrome (SGBS), an X-linked disorder characterized by pre- and postnatal overgrowth and various visceral and skeletal dysmorphisms. Some of these dysmorphisms could be the result of deficient growth inhibition or apoptosis in certain cell types during development. Here we present evidence indicating that OCI-5/GPC3 induces apoptosis in cell lines derived from mesothelioma (II14) and breast cancer (MCF-7). This induction, however, is cell line specific since it is not observed in NIH 3T3 fibroblasts or HT-29 colorectal tumor cells. We also show that the apoptosis-inducing activity in II14 and MCF-7 cells requires the anchoring of OCI-5/GPC3 to the cell membrane. The glycosaminoglycan chains, on the other hand, are not required. MCF-7 cells can be rescued from OCI-5/GPC3–induced cell death by insulin-like growth factor 2. This factor has been implicated in Beckwith-Wiedemann, an overgrowth syndrome that has many similarities with SGBS. The discovery that OCI-5/GPC3 is able to induce apoptosis in a cell line– specific manner provides an insight into the mechanism that, at least in part, is responsible for the phenotype of SGBS patients.

[1]  T. Ludwig,et al.  Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. , 1997, Genes & development.

[2]  S. Selleck,et al.  dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. , 1997, Development.

[3]  A. Lander,et al.  Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. , 1997, Developmental biology.

[4]  R. Brodsky,et al.  Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  X. Guillonneau,et al.  FGF2-stimulated release of endogenous FGF1 is associated with reduced apoptosis in retinal pigmented epithelial cells. , 1997, Experimental cell research.

[6]  A. Admon,et al.  Identification of Glypican as a Dual Modulator of the Biological Activity of Fibroblast Growth Factors* , 1997, The Journal of Biological Chemistry.

[7]  D. Hicks,et al.  Cell-cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c-myc-independent apoptosis. , 1997, British Journal of Cancer.

[8]  J. Filmus,et al.  OCI-5/Rat Glypican-3 Binds to Fibroblast Growth Factor-2 but Not to Insulin-like Growth Factor-2* , 1997, The Journal of Biological Chemistry.

[9]  P. Marynen,et al.  Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. , 1997, Genomics.

[10]  M. Raff,et al.  Programmed Cell Death in Animal Development , 1997, Cell.

[11]  R. Lavker,et al.  EGF-R dependent regulation of keratinocyte survival. , 1997, Journal of cell science.

[12]  D. Schlessinger,et al.  Simpson-Golabi-Behmel syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. , 1996, American journal of medical genetics.

[13]  M. Salmivirta,et al.  Heparan sulfate : a piece of information , 2004 .

[14]  K. Kinzler,et al.  Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.

[15]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[16]  H. van den Berghe,et al.  Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican , 1996, The Journal of cell biology.

[17]  A. Levine,et al.  Analysis of wild-type and mutant p21WAF-1 gene activities , 1996, Molecular and cellular biology.

[18]  R. Weksberg,et al.  Glypicans: a growing trend , 1996, Nature Genetics.

[19]  D. Schlessinger,et al.  Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome , 1996, Nature Genetics.

[20]  K. Kinzler,et al.  Erratum: Genetic determinants of p53-induced apoptosis and growth arrest ((Genes and Development (1996) 10 (1945-1952)) , 1996 .

[21]  R. Weksberg,et al.  Infantile lethal variant of Simpson-Golabi-Behmel syndrome associated with hydrops fetalis. , 1995, American journal of medical genetics.

[22]  S. Selleck,et al.  The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division patterning during postembryonic development of the nervous system in Drosophila. , 1995, Development.

[23]  J. Filmus,et al.  Identification of a new membrane-bound heparan sulphate proteoglycan. , 1995, The Biochemical journal.

[24]  K. Watanabe,et al.  K-glypican: a novel GPI-anchored heparan sulfate proteoglycan that is highly expressed in developing brain and kidney , 1995, The Journal of cell biology.

[25]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[26]  L. Koulischer,et al.  Clinical overlap of Beckwith‐Wiedemann, Perlman and Simpson‐Golabi‐Behmel syndromes: a diagnostic pitfall , 1995, Clinical genetics.

[27]  A. Robles,et al.  Induction of cyclin D1 overexpression by activated ras. , 1994, Oncogene.

[28]  G. Evan,et al.  c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.

[29]  A. Lander,et al.  Cerebroglycan: an integral membrane heparan sulfate proteoglycan that is unique to the developing nervous system and expressed specifically during neuronal differentiation , 1994, The Journal of cell biology.

[30]  B. Olwin,et al.  [11] Regulation by heparan sulfate in fibroblast growth factor signaling , 1994 .

[31]  B. Olwin,et al.  Regulation by heparan sulfate in fibroblast growth factor signaling. , 1994, Methods in enzymology.

[32]  M. Gossen,et al.  Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements. , 1994, Trends in biochemical sciences.

[33]  G. David.  Integral membrane heparan sulfate proteoglycans , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  T. Wight,et al.  The role of proteoglycans in cell adhesion, migration and proliferation , 1992, Current Biology.

[35]  G. Neri,et al.  Further delineation of the Simpson-Golabi-Behmel (SGB) syndrome. , 1992, American journal of medical genetics.

[36]  J. Bodurtha,et al.  Report of another family with Simpson-Golabi-Behmel syndrome and a review of the literature. , 1992, American journal of medical genetics.

[37]  J. Allanson,et al.  Simpson-Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. , 1992, American journal of medical genetics.

[38]  P. Marynen,et al.  Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts , 1990, The Journal of cell biology.

[39]  S. Nagata,et al.  pEF-BOS, a powerful mammalian expression vector. , 1990, Nucleic acids research.

[40]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[41]  D. Carey,et al.  Membrane anchoring of heparan sulfate proteoglycans by phosphatidylinositol and kinetics of synthesis of peripheral and detergent-solubilized proteoglycans in Schwann cells , 1989, The Journal of cell biology.

[42]  J. Church,et al.  Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine , 1988, Molecular and cellular biology.